Amicus Therapeutics, Inc. (NASDAQ: FOLD)

Amicus Therapeutics, Inc. is a global biotechnology company dedicated to developing and delivering therapies for patients with rare diseases. The company focuses on lysosomal storage disorders, particularly Fabry disease and Pompe disease, through its portfolio of oral and enzyme based treatments. Its commercial products include Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease, which together generate the majority of its revenue. Beyond marketed therapies, Amicus advances a pipeline that features DMX 200, an oral investigational agent for focal segmental glomerulosclerosis, and explores next generation chaperones and gene therapy approaches. The company’s mission centers on transforming the treatment landscape for underserved patient populations worldwide.

The company generates revenue primarily from the sale of its two approved products. Galafold (migalastat) is an oral monotherapy for Fabry disease, while Pombiliti plus Opfolda (cipaglucosidase alfa atga/miglustat) is a two component therapy for late onset Pompe disease. For the year ended December 31 2025, Galafold generated $521.7 million in sales and Pombitili plus Opfolda contributed $112.5 million, together representing the bulk of total revenue. Additional revenue stems from licensing agreements, such as the exclusive U. S. rights to Dimerix’s DMX 200, which included an upfront payment of $30 million and potential milestones and royalties. The company’s products are commercialized in over 40 countries across North America, Europe, Asia and other regions, supported by a network of specialty distributors and reimbursement agreements with health authorities.

Amicus Therapeutics holds a niche position in the rare disease therapeutics market, where it competes with larger enzyme replacement therapy providers and emerging gene therapy companies. Principal competitors include Sanofi, which markets Fabrazyme for Fabry disease and Myozyme/Lumizyme and Nexviazyme for Pompe disease; Takeda, which offers Replagal for Fabry disease; and Chiesi, which sells ELFABRIO for Fabry disease. Additional competition comes from Idorsia with its oral glucosylceramide synthase inhibitor Lucerastat for Fabry disease and from several gene based programs targeting Pompe and Fabry diseases. The company’s competitive advantages stem from its oral pharmacological chaperone approach for Fabry disease, which offers a non invasive alternative to biweekly infusions, and from its novel two component therapy for Pompe disease that aims to improve enzyme uptake and stability. These differentiators are reinforced by a robust intellectual property portfolio, including patents on migalastat that extend to 2042 and on cipaglucosidase alfa that run to 2038, providing exclusivity in key markets. Furthermore, Amicus benefits from established reimbursement agreements in multiple jurisdictions and a commercial team experienced in launching orphan drugs worldwide. These factors collectively support its standing among peers and enable sustained growth in the rare disease sector.

The company serves patients diagnosed with Fabry disease and Pompe disease, as well as the healthcare providers who treat them, including hospitals, specialty clinics, infusion centers, and physician practices that focus on metabolic disorders. Reimbursement from private insurers and government programs such as Medicare and Medicaid also constitutes a key part of its customer base, as access to funding influences prescription and treatment decisions. While specific customer names are not disclosed in the filing, the broad base of individuals living with these rare conditions and the institutions involved in their care underpins its commercial operations and drives ongoing demand for its therapies.